#United States #New York #Immunic #IMU-856 #Vidofludimus

Immunic's Upcoming Conferences in October 2025

Immunic, Inc. (Nasdaq: IMUX) is gearing up for a busy October as it participates in several important scientific and investor conferences. The biotechnology company, which is focused on developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases, plans to showcase its latest research and advancements.

UEGW 2025: United European Gastroenterology Week

From October 4 to 7, Immunic's research and development team will attend the United European Gastroenterology Week (UEGW) 2025 in Berlin, Germany. This event is a significant platform for discussing the latest developments in gastrointestinal science and medicine.

At this conference, data regarding IMU-856—an orally available small molecule that modulates SIRT6—will be presented. This data includes:

• - Presentation Title: IMU-856, an Orally Available Epigenetic Modulator of Barrier Regeneration, Showed Positive Effects on Gut Hormone Levels in Celiac Disease Patients in a Phase 1 Clinical Study
• - Presenting Author: Amelie Schreieck, Ph.D., Senior Manager of Biomarker Development at Immunic
• - Presentation Details: Oral presentation scheduled for October 6, 2025 at 8:30 - 9:30 AM CEST. The session will focus on understanding the mechanisms of molecular medicine.

Additionally, there will be an ePoster titled Biomarkers of Extracellular Matrix Remodeling Reflect Pharmacodynamic Effects of IMU-856, presented by Marta Sorokina Alexdόttir, Ph.D., during the poster session on October 4, 2025 from 9:00 AM to 5:00 PM CEST.

International Society of Neuroimmunology (ISNI) Congress

Following UEGW, from October 5 to 8, Immunic will also be participating in the 17th International Congress of the International Society of Neuroimmunology in Chiba, Japan. Here, Evelyn Peelen, Ph.D., Head of Research, will present data on vidofludimus calcium (IMU-838), the company’s lead product. This presentation will cover:

• - Title: Nurr1 Activator Vidofludimus Calcium Exhibits Signs of Neuroprotection in Preclinical Models
• - Abstract ID: 213
• - Session Date: October 7, 2025, from 6:20 - 7:40 PM JST.

The efficacy of this treatment is pivotal as it targets neurodegenerative pathways, combining neuroprotective and anti-inflammatory properties.

Roth’s 4th Annual Healthcare Opportunities Conference

The month will conclude with Roth’s 4th Annual Healthcare Opportunities Conference on October 9, 2025 in New York. Daniel Vitt, Ph.D., CEO of Immunic, will engage in a panel discussion titled Next Wave of Innovation in Underserved Indications at 2:00 - 2:55 PM ET. This conference provides an excellent opportunity for investors to gain insights into Immunic’s strategic outlook and development pipeline as Dr. Vitt and Glenn Whaley, CFO, also partake in one-on-one investor meetings.

H.C. Wainwright Virtual Fireside Chat

Additionally, on October 23, 2025, Immunic will host a virtual fireside chat, featuring Dr. Vitt and Jason Tardio, President and COO. This session will be accessible to the public, allowing a broader audience to engage with the company's strategic vision and prospects.

About Immunic, Inc.

Immunic, Inc. is dedicated to the development of therapies targeting chronic inflammatory and autoimmune diseases. The promising vidofludimus calcium, currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, has shown potential in improving patient outcomes and is expected to report top-line data by the end of 2026. The company remains committed to advancing innovative treatments, with IMU-856 also in focus for facilitating intestinal barrier function recovery.

Stay tuned for updates as Immunic continues to lead advancements in the biotechnology space, offering solutions for unmet medical needs. For more information, you can visit Immunic's Official Website.